Ergomed plc Notice of Interim Results (3927J)
23 Agosto 2021 - 01:00AM
UK Regulatory
TIDMERGO
RNS Number : 3927J
Ergomed plc
23 August 2021
PRESS RELEASE
Notice of Interim Results
Guildford, UK - 23 August 2021: Ergomed plc, (LSE: ERGO)
("Ergomed" or the "Company"), a company focused on providing
specialised services to the pharmaceutical industry, will announce
its interim results for the six months ending 30 June 2021 on 28
September 2021.
Miroslav Reljanović, Executive Chairman, and Richard Barfield,
Chief Financial Officer, will host a virtual presentation and
conference call for analysts at 10.30am BST on the day of the
results.
ENDS
Enquiries :
Ergomed plc Tel: +44 (0) 1483 402 975
Miroslav Reljanović (Executive Chairman)
Richard Barfield (Chief Financial Officer)
Numis Securities Limited Tel: +44 (0) 20 7260 1000
Freddie Barnfield / Matthew O'Dowd (Nominated Adviser)
James Black (Broker)
Peel Hunt LLP Tel: +44 (0) 20 7418 8900
James Steel / Dr. Christopher Golden
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner / Matthew Neal ergomed@consilium-comms.com
Angela Gray
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical
industry spanning all phases of clinical development, post-approval
pharmacovigilance and medical information. Ergomed's fast-growing
services business includes an industry-leading suite of specialist
pharmacovigilance (PV) solutions, integrated under the
PrimeVigilance brand and a full range of high-quality clinical
research and trial management services under the Ergomed brand
(CRO). For further information, visit: http://ergomedplc.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORDBGDIUBDDGBD
(END) Dow Jones Newswires
August 23, 2021 02:00 ET (06:00 GMT)
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Ergomed (LSE:ERGO)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024